Cidara Therapeutics/$CDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
$CDTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
38
ISIN
US1717572069
Website
CDTX Metrics
BasicAdvanced
$312M
-
-$20.89
0.86
-
Price and volume
Market cap
$312M
Beta
0.86
52-week high
$28.42
52-week low
$10.14
Average daily volume
153K
Financial strength
Current ratio
3.869
Quick ratio
3.48
Long term debt to equity
0.872
Total debt to equity
1.887
Management effectiveness
Return on assets (TTM)
-55.20%
Return on equity (TTM)
-299.58%
Valuation
Price to revenue (TTM)
697.587
Price to book
2.07
Price to tangible book (TTM)
2.07
Price to free cash flow (TTM)
-1.098
Growth
Revenue change (TTM)
-98.33%
Earnings per share change (TTM)
160.44%
3-year revenue growth (CAGR)
-82.28%
3-year earnings per share growth (CAGR)
10.79%
What the Analysts think about CDTX
Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.
CDTX Financial Performance
Revenues and expenses
CDTX Earnings Performance
Company profitability
CDTX News
AllArticlesVideos
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
GlobeNewsWire·1 month ago
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
GlobeNewsWire·1 month ago
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $312M as of June 06, 2025.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of June 06, 2025.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.